Why CSL shares are this fundie's top ASX 200 healthcare pick

CSL is about to start marketing the world's most expensive drug after gaining official approval for use in the United States last week.

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Many experts have recently rated CSL a buy with ambitious share price targets 
  • The cost of CSL's newly-approved drug Hemgenix will be US$3.5 million per dose, reportedly making it the world's most expensive drug 
  • The CSL share price crossed the $300 mark for only the third time in 2022 last Friday, and it has closed above $300 every day this week 

The CSL Limited (ASX: CSL) share price has closed above the $300 threshold all week, and today it's currently trading at $302.17, up 1.2% for the day so far.

Meantime the S&P/ASX 200 Index (ASX: XJO) is down 0.65%.

In an interview with Livewire this week, Wilson Asset Management equity analyst Anna Milne said CSL was her top ASX healthcare share pick for 2023.

Why this expert backs CSL ahead of other ASX 200 options

Milne joins a bunch of other brokers who are also tipping CSL shares for growth next year.

When asked about her top healthcare stock pick for 2023, Milne said:

I know it probably feels like a consensus call but it's got to be CSL.

Earnings are set to grow almost 30% next year, 15% the year after that and 10% in FY 2025 and beyond.

Seqirus is also set up for a strong year from flu season, and Vifor is a compelling medium-term growth lever. It's a stock that's hard to fault.

Who else is tipping growth for the CSL share price in 2023?

Wilsons is tipping a 12-month share price target of $327 for CSL shares and has an overweight rating.

As my colleague James reports, Citi has reaffirmed its buy rating with a share price target of $340. Macquarie retains its outperform rating but recently upped its price target by 4.1% to $343.

Tribeca portfolio manager Jun Bei Liu says CSL shares are among the best ASX shares to buy and hold for several years. Liu says: "Even if we have a US recession or a global recession, it's not going to slow down. It will grow double digits for the next three years."

Blake Henricks, portfolio manager at Firetrail Investments, said CSL is a defensive share that can ride out any future market volatility. He says: "It's large, it's liquid, it's healthcare. So to me, it ticks all the defensive boxes. It's in a defensive growth category."

What's been happening with CSL lately?

The big news of late has been the approval of CSL's unique haemophilia B treatment, called Hemgenix, by the United States Food and Drug Administration.

This drug is a big deal because it's the first and only one-time gene therapy to become available for adults with haemophilia B. A commercial launch is expected in FY24.

According to the Australian Financial Review (AFR), Hemgenix will be priced at US$3.5 million per dose.

Um, what?

Yes, indeed. It will be the world's most expensive drug, according to the article.

Of course, this isn't the price that US patients will pay. It's what health insurers and government programs like Medicare will pay in exchange for the greater cost savings the treatment will deliver to them.

CSL head of research and development Bill Mezzanotte told the AFR the cost to CSL of bringing Hemgenix to market after more than 10 years in development was more than $US1 billion.

He also argues the enormous value to the healthcare system given the patient population size and the long-term efficacy of a single dose, which will replace multiple doses of other drugs per patient, per week.

Dr Mezzanotte said:

You can't even measure the difference in a person's life taking one treatment and not need to think about it for at least 10 to 20 years [versus multiple times a week].

It's not just their convenience, it's their sense of mental security, and of course, it saves the healthcare system a lot of money in both the cost of therapy, rescue therapies, the cost of treating a bleed and also the lost productivity of these patients.

According to the article, a 2021 study published in the Journal of Medical Economics found it cost the healthcare system more than US$20 million to treat a moderate to severe haemophilia B patient over their lifetime.

CSL share price snapshot

CSL shares crossed the $300 mark for only the third time in 2022 last week.

Immediately before COVID-19 hit the Australian share market, the CSL share price was about $340.

Motley Fool contributor Bronwyn Allen has positions in Csl. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Csl. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »